Polanski Malu, Anderson N Leigh
The Plasma Proteome Institute, P.O. Box: 53450, Washington DC, 20009-3450, USA.
Biomark Insights. 2007 Feb 7;1:1-48.
We have compiled from literature and other sources a list of 1261 proteins believed to be differentially expressed in human cancer. These proteins, only some of which have been detected in plasma to date, represent a population of candidate plasma biomarkers that could be useful in early cancer detection and monitoring given sufficiently sensitive specific assays. We have begun to prioritize these markers for future validation by frequency of literature citations, both total and as a function of time. The candidates include proteins involved in oncogenesis, angiogenesis, development, differentiation, proliferation, apoptosis, hematopoiesis, immune and hormonal responses, cell signaling, nucleotide function, hydrolysis, cellular homing, cell cycle and structure, the acute phase response and hormonal control. Many have been detected in studies of tissue or nuclear components; nevertheless we hypothesize that most if not all should be present in plasma at some level. Of the 1261 candidates only 9 have been approved as "tumor associated antigens" by the FDA. We propose that systematic collection and large-scale validation of candidate biomarkers would fill the gap currently existing between basic research and clinical use of advanced diagnostics.
我们从文献及其他来源汇编了一份1261种蛋白质的清单,这些蛋白质被认为在人类癌症中存在差异表达。这些蛋白质中,迄今只有部分在血浆中被检测到,它们代表了一批候选血浆生物标志物。如果有足够灵敏的特异性检测方法,这些标志物在癌症早期检测和监测中可能会很有用。我们已开始根据文献引用频率(包括总引用次数以及随时间变化的引用次数)对这些标志物进行排序,以便未来进行验证。候选蛋白质包括参与肿瘤发生、血管生成、发育、分化、增殖、凋亡、造血、免疫和激素反应、细胞信号传导、核苷酸功能、水解作用、细胞归巢、细胞周期与结构、急性期反应以及激素调控的蛋白质。许多蛋白质已在组织或核成分研究中被检测到;然而,我们推测大多数(即便不是全部)在血浆中应该会在某种程度上存在。在这1261种候选蛋白质中,只有9种已被美国食品药品监督管理局批准为“肿瘤相关抗原”。我们提议,对候选生物标志物进行系统收集和大规模验证,将填补目前基础研究与先进诊断临床应用之间存在的差距。